Clinical trialCLINICALTRIALSMar 26
Trial Now Recruiting: Human Amniotic-Derived Mesenchymal Stem Cell Therapy for Calciphylaxis (NCT04592640)
Researchers are testing a new treatment for calciphylaxis, a serious condition where calcium builds up in blood vessels and skin tissue, causing painful sores. The treatment uses special cells from amniotic fluid (the fluid around a baby during pregnancy) to see if they can help heal the damage. This is an early-stage trial with a small group of 9 patients to check if the treatment is safe and works.
WHY IT MATTERSCalciphylaxis has very few treatment options and high mortality rates — this trial offers patients with chronic kidney disease a chance to access an experimental stem cell therapy that could reduce tissue damage and improve survival.